Mission Wealth Management LP Takes $360,000 Position in IQVIA Holdings Inc. (NYSE:IQV)

Mission Wealth Management LP bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 1,556 shares of the medical research company’s stock, valued at approximately $360,000.

A number of other institutional investors have also added to or reduced their stakes in IQV. Silver Oak Securities Incorporated grew its holdings in IQVIA by 1,046.8% in the fourth quarter. Silver Oak Securities Incorporated now owns 2,844 shares of the medical research company’s stock worth $658,000 after purchasing an additional 2,596 shares during the last quarter. Stonebrook Private Inc. purchased a new stake in shares of IQVIA during the fourth quarter worth about $706,000. Unique Wealth Strategies LLC purchased a new position in shares of IQVIA in the 4th quarter valued at approximately $1,841,000. Consolidated Planning Corp boosted its stake in IQVIA by 9.0% in the 4th quarter. Consolidated Planning Corp now owns 8,008 shares of the medical research company’s stock worth $1,853,000 after purchasing an additional 660 shares in the last quarter. Finally, Dohj LLC purchased a new stake in IQVIA during the 4th quarter worth approximately $943,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of NYSE IQV opened at $223.39 on Friday. The firm has a market cap of $40.55 billion, a PE ratio of 30.52, a PEG ratio of 2.15 and a beta of 1.52. The firm has a fifty day moving average of $244.56 and a 200 day moving average of $223.84. The company has a debt-to-equity ratio of 2.02, a quick ratio of 0.86 and a current ratio of 0.88. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, topping the consensus estimate of $2.82 by $0.02. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The firm had revenue of $3.87 billion during the quarter, compared to analysts’ expectations of $3.80 billion. During the same period in the previous year, the business earned $2.54 earnings per share. The firm’s revenue for the quarter was up 3.5% on a year-over-year basis. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.12 EPS for the current fiscal year.

Insiders Place Their Bets

In other IQVIA news, insider Ari Bousbib sold 31,678 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the sale, the insider now directly owns 796,752 shares in the company, valued at approximately $199,610,278.56. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other IQVIA news, insider Kevin C. Knightly sold 8,607 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total value of $2,153,213.19. Following the transaction, the insider now owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the sale, the insider now owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The disclosure for this sale can be found here. Insiders have sold 41,285 shares of company stock valued at $10,331,003 in the last ninety days. 1.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. SVB Leerink initiated coverage on shares of IQVIA in a report on Monday, February 26th. They set an “outperform” rating and a $290.00 price objective on the stock. BTIG Research began coverage on IQVIA in a research report on Tuesday, February 13th. They issued a “buy” rating and a $285.00 target price on the stock. Barclays raised their price target on shares of IQVIA from $260.00 to $265.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. Finally, Evercore ISI decreased their target price on shares of IQVIA from $275.00 to $250.00 and set an “outperform” rating for the company in a research report on Friday. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $257.57.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.